Erratum: Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Journal of Affective Disorders (2010) 121:1 (106-115) DOI: 10.1016/j.jad.2009.10.007);Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

Journal of Affective Disorders

Volumn 121, Issue 1-2, 2010, Pages 106-115

  Suppes, Trisha ^a   Datto, Catherine ^b   Minkwitz, Margaret ^b   Nordenhem, Arvid ^c   Walker, Chris ^b   Darko, Denis ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BIOVITRUM AB   (Sweden)

Author keywords

Bipolar disorder; depression; monotherapy; quetiapine; Depression; Monotherapy; Quetiapine

Indexed keywords

PLACEBO; QUETIAPINE;

ACUTE DISEASE; ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEATH; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA;

EID: 72649090783     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.07.007     Document Type: Erratum

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), text revision (2000), American Psychiatric Association, Washington DC
2. Baldessarini R.J., Perry R., and Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum. Psychopharmacol. 23 (2008) 95-105
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
4. Burton S.C. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J. Psychiatr. Pract. 11 (2005) 369-378
5. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 (2005) 1351-1360
6. Calabrese J.R., Huffman R.F., White R.L., Edwards S., Thompson T.R., Ascher J.A., Monaghan E.T., and Leadbetter R.A. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 10 (2008) 323-333
7. Calabrese J.R., Hirschfeld R.M., Frye M.A., and Reed M.L. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J. Clin. Psychiatry 65 (2004) 1499-1504
8. Cutler A., Datto C., Nordenhem A., Minkwitz M., Dettore B., Acevedo L., and Darko D. Effectiveness of an extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania. Poster presented at the 161st Annual Meeting of the American Psychiatric Association, May 3-8, 2008; Washington, DC, USA (2008)
9. Fincke B.J., Miller D.R., and Spiro A. The interaction of patient perception of overmedication with drug compliance and side effects. J. Gen. Intern. Med. 13 (1998) 182-185
10. Goldstein J.M., Christoph G., Grimm S., Liu J.W., Widzowski D., and Brecher M. Unique mechanism for the antidepressant properties of the atypical antipsychotic quetiapine. Presented at the 20th European College of Neuropsychopharmacology, October 2007, Vienna, Austria (2007)
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
12. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Leon A.C., Solomon D.A., Coryell W., Maser J.D., and Keller M.B. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 62 (2005) 1322-1330
13. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., and Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60 (2003) 261-269
14. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., and Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002) 530-537
15. Kessler R.C., Akiskal H.S., Ames M., Birnbaum H., Greenberg P., Hirschfeld R.M., Jin R., Merikangas K.R., Simon G.E., and Wang P.S. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163 (2006) 1561-1568
16. Kupka R.W., Altshuler L.L., Nolen W.A., Suppes T., Luckenbaugh D.A., Leverich G.S., Frye M.A., Keck Jr. P.E., McElroy S.L., Grunze H., and Post R.M. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 9 (2007) 531-535
17. Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck Jr. P.E., Kupka R.W., Denicoff K.D., Nolen W.A., Grunze H., Martinez M.I., and Post R.M. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 163 (2006) 232-239
18. McElroy S., Olausson B., Chang W., Nordenhem A., Paulsson B., Brecher M., and Young A.H. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II) [Poster]. Presented at the 3rd Biennial International Society for Bipolar Disorders (ISBD) Meeting, Delhi, India. [Poster # 106] (2008)
19. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., and Kessler R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64 (2007) 543-552
20. Montgomery S.A., and Asberg M.A. new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
21. Post R.M., Denicoff K.D., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T.M., Rush A.J., Keck Jr. P.E., McElroy S.L., Luckenbaugh D.A., Pollio C., Kupka R., and Nolen W.A. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry 64 (2003) 680-690
22. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., Rahman Z., Ring R.H., and Schechter L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther. 113 (2007) 134-153
23. Simpson G.N., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 suppl 44 (1970) 11-19
24. Spearing M.K., Post R.M., Leverich G.S., Brandt D., and Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73 (1997) 159-171
25. Suppes T., Vieta E., Liu S., and Brecher P.B. Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127). Am. J. Psychiatry 166 (2009) 476-488
26. Thase M.E., Jonas A., Khan A., Bowden C.L., Wu X., McQuade R.D., Carson W.H., Marcus R.N., and Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized placebo-controlled studies. J. Clin. Psychopharmacol. 28 (2008) 13-20
27. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., Calabrese J.R., and BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26 (2006) 600-609
28. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 (2003) 1079-1088
29. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. N. Engl. J. Med. 358 (2008) 252-260
30. Vieta E., Suppes T., Eggens I., Persson I., Paulsson B., Brecher M., and On behalf of the Trial 126 Study Investigators. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109 (2008) 251-263
31. Young A.H., McElroy S., Chang W., Olausson B., Paulsson B., and Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I) [Poster]. Presented at the 3rd Biennial International Society for Bipolar Disorders (ISBD) Meeting, Delhi, India. [Poster # 79] (2008)
32. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435